Clin2
NCT06665074Worth exploringRecruiting

Inflammation and aggression study

Intermittent Explosive Disorder

Treatments studied

Part of Mental health clinical trials.

This trial tests how inflammation affects aggression by giving a small amount of a substance that briefly triggers your immune system. You may qualify if you have a diagnosis of Intermittent Explosive Disorder (IED), or if you are a healthy control without current anger issues.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
112 people
Ages
21 years to 55 years
Study type
Interventional

Who can take part

  • You are between 21 and 55 years old.
  • You are generally healthy with no major medical conditions.
  • You are not taking any prescription medications for at least 4 weeks before the study.
  • If you have IED, you must have a history of aggression (score over 12 on a standard test).
  • If you are a control, you cannot have IED and must have low aggression scores (under 11).
  • You are not pregnant, breastfeeding, or planning pregnancy within 9 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06118567Recruiting· Phase 2
Does nitrous oxide help with aggression?

This study tests if a single dose of nitrous oxide (laughing gas) can reduce aggression in people with intermittent explosive disorder (IED). It compares their reactions to healthy volunteers without aggression issues.

Columbus, Ohio
NCT06118580Recruiting· Phase 2
Alcohol and aggression brain study

This study looks at how alcohol affects the brain in people with a history of aggression or alcohol use disorder. You may be able to join if you're a right-handed adult who drinks regularly and fits one of the specific groups being studied.

Columbus, Ohio
NCT05895513Recruiting· Phase 2
Pimavanserin trial for aggression and social thinking

This Phase 2 trial tests pimavanserin, a medication that may affect brain signals, to see if it can reduce aggression and improve social thinking in people with intermittent explosive disorder (IED) or a history of aggressive behavior. If you qualify, you’ll be screened with medical tests and questionnaires and must meet medication and safety rules to participate.

Columbus, Ohio
NCT02392442Enrolling by invitation· Phase 2
Study drug-free lung irritation using endotoxin in healthy adults

This trial tests how putting a small amount of endotoxin into a specific part of the lung affects the body. It’s designed for healthy, nonsmoking adults, and may help researchers understand lung and immune responses.

Bethesda, Maryland
NCT01143480Recruiting
Testing how the body responds to endotoxin

This study checks how your immune system (your body’s defense system) reacts to a controlled substance that triggers inflammation. It may help researchers understand why some people have stronger or weaker inflammatory responses.

Research Triangle Park, North Carolina
NCT07713641Recruiting
Testing gut bacteria's effect on brain function and inflammation

This trial looks at whether short-chain fatty acids (substances made by gut bacteria) can reduce inflammation and improve thinking skills (executive function). You'll receive an injection that causes mild, temporary inflammation (like a bad cold) and complete cognitive tasks.

Leuven

Hear when a new Intermittent Explosive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.